Table 1.
Demographic characteristics, clinical, and laboratory parameters of the study group.
| Total group (n: 1,755) | Women (n: 1,578) | Men (n: 177) | P | |
|---|---|---|---|---|
| Age (years) | 46.9 ± 13.2 | 46 ± 12 | 49 ± 0.9 | n.s. |
| BMI (kg/m2) | 28.9 ± 6.1 | 29.0 ± 5.9 | 28.5 ± 7.1 | n.s. |
| Duration of disease (years) | 5.83 ± 5.1 | 5.9 ± 4.5 | 5.1 ± 4.2 | n.s. |
| LT4 daily dosage (μg/day) | 96.0 ± 47.9 | 94.9 ± 47 | 103.7 ± 49 | n.s. |
| LT4 dosage per kg (μg/kg) | 1.28 ± 0.64 | 1.27 ± 0.62 | 1.36 ± 0.7 | 0.001 |
| fT4 (ng/dL) | 1.24 ± 0.37 | 1.24 ± 0.36 | 1.29 ± 0.41 | n.s. |
| TSH (mIU/L) | 4.6 ± 11 | 4.5 ± 10 | 5.2 ± 17 | n.s. |
| <0.5 mIU/L, n (%) | 327 (18.6) | 280 (17.7) | 47 (26.5) | n.s. |
| 0.5–4 mIU/L, n (%) | 950 (54.1) | 874 (55.3) | 76 (42.9) | n.s. |
| 4–10 mIU/L, n (%) | 337 (19.2) | 303 (19.2) | 34 (19.2) | n.s. |
| >10 mIU/L, n (%) | 141 (8.1) | 121 (7.6) | 20 (11.2) | 0.01 |
BMI, body mass index; LT4, levothyroxine; fT4, free T4; TSH, thyroid-stimulating hormone.